Skip to main content

Radionuclide Decorporation and Chelation

By Troy Zhou, PhD, DABR, DABSNM
• 16 min read

When a radionuclide is taken into the body, washing the skin does not help — the dose is delivered from the inside until the material decays or is excreted. Decorporation is the set of medical countermeasures that speeds that excretion and lowers the committed dose, and its defining feature is that it works best when it starts early, often before the dose is even fully estimated.

Most radiation-safety effort in a medical facility is aimed at external exposure and surface contamination. But inhalation of an aerosol, ingestion, or a contaminated wound can deposit radioactive material internally, where time, distance, and shielding no longer apply. The only levers left are radioactive decay, natural biological clearance, and decorporation 1, 5.

This guide explains how internal contamination is assessed, the mechanisms and agents used to enhance excretion, why timing dominates effectiveness, and how a facility should build this capability into its radiation protection and emergency program. DRPS supports facilities on internal-dosimetry and emergency-preparedness questions through its radiation safety officer and radiation safety training services across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware.

Introduction

Internal contamination occurs when radioactive material crosses the body's boundaries — through the lungs, the gastrointestinal tract, intact or broken skin, or a wound. Once absorbed, a radionuclide distributes according to its chemistry: cesium behaves like potassium and spreads through soft tissue, strontium and radium seek bone, radioiodine concentrates in the thyroid, and the actinides (plutonium, americium, curium) deposit in bone and liver with very long retention 1, 5.

From that point, the committed dose is set by how much was taken in, where it goes, and how long it stays. Decorporation attacks the last factor: by chemically capturing the radionuclide or blocking its uptake, it shortens the biological residence time and reduces the dose that would otherwise be delivered over the coming weeks, months, or years. Because the actinides and cesium-137 have long effective half-lives, the potential dose savings from prompt treatment can be large 1, 6.

Topic Explanation

Assessment comes first

Decorporation is a medical decision built on a health-physics assessment. The radiation safety officer or health physicist estimates the intake — the activity that entered the body — using bioassay (urine and fecal sampling), nasal swabs, wound counting, and, for penetrating emitters, whole-body or thyroid counting. The intake is compared against reference quantities such as the annual limit on intake (ALI), the clinical decision guide (CDG), or a derived reference level to judge severity 1.

A first-order intake estimate can be made at the bedside by measuring activity, converting counts to disintegrations using a radionuclide-specific gamma-ray constant, and comparing to the clinical decision guide, as described in the internal-contamination management literature 5. For the measurement and bioassay side of this work, see internal dose assessment and bioassay and thyroid bioassay for I-131 workers.

The committed dose being averted

Internal exposure is quantified as committed effective dose, the total effective dose integrated over 50 years (adults) from an intake. It is computed from the intake and a radionuclide- and route-specific dose coefficient:

where is the intake in becquerels and is the committed effective dose coefficient in sieverts per becquerel, tabulated by the ICRP for each radionuclide, chemical form, and intake pathway 7. Decorporation reduces the effective intake that is retained, and the benefit is expressed as averted dose — the difference between the committed dose without treatment and with treatment 1, 6.

Worked example (illustrative inputs). Suppose a worker's assessed committed effective dose from an inhaled actinide, untreated, is estimated at Sv, and prompt chelation is assessed to remove 40% of the retained material before it is fixed in tissue. The averted dose is

leaving a committed dose of about 0.30 Sv. The achievable fraction depends heavily on how soon treatment begins — the central theme below — and on the radionuclide's chemistry; these inputs are illustrative, and actual assessments use the ICRP coefficients and biokinetic models for the specific case 1, 6, 7.

Key Technical Principles

Four mechanisms of countermeasure

Decorporation and related countermeasures work through four distinct physical and chemical mechanisms:

  1. Chelation — a chelating molecule forms a stable, water-soluble complex with a metal radionuclide, which is then excreted (mainly renally). This is the mechanism of DTPA for the actinides.
  2. Ion exchange / mobilization — an insoluble binder in the gut traps the radionuclide and interrupts its enterohepatic recirculation, shifting the balance toward fecal excretion. This is the mechanism of Prussian blue for cesium and thallium.
  3. Blocking / dilution / displacement — a stable isotope or chemical analog saturates the uptake pathway so the radionuclide is not retained. Potassium iodide blocks thyroid uptake of radioiodine; oral phosphates and strontium/calcium loading can reduce strontium retention.
  4. Physical removal — gentle wound irrigation and surgical excision of contaminated tissue, and, for insoluble inhaled particles with high activity, bronchoalveolar lavage 5.

DTPA for the actinides

Calcium- and zinc-DTPA (pentetate calcium trisodium and pentetate zinc trisodium) are the FDA-approved chelators for internal contamination with plutonium, americium, or curium, approved in 2004 2, 3. The calcium form, Ca-DTPA, is more effective in the first 24 hours and is given as a single 1.0 g intravenous initial dose in adults and adolescents (pediatric dosing 14 mg/kg, not to exceed 1.0 g); the zinc form, Zn-DTPA, is preferred for maintenance therapy after the first 24 hours because it depletes fewer endogenous trace metals 2, 3. Ca-DTPA carries a boxed warning that nebulized administration may be associated with asthma exacerbation, and chelation can deplete trace metals such as zinc and manganese 2.

Prussian blue for cesium and thallium

Insoluble Prussian blue (ferric hexacyanoferrate, marketed as Radiogardase) is the FDA-approved treatment for cesium-137 or thallium contamination, approved on October 2, 2003 — the first new drug approved specifically for radiation-contamination treatment 4. It is supplied as 500 mg oral capsules; the adult regimen is 3 g three times daily, continued for 30 days or longer, with duration guided by follow-up urine and fecal measurements 4. It is not absorbed; it works entirely in the gut by ion exchange, so its main side effects are constipation and blue-colored stool 4.

Timing dominates effectiveness

The single most important principle is that earlier treatment averts more dose. Once a radionuclide is absorbed and fixed in tissue, chelation and binding become far less effective. A biokinetic simulation of DTPA and Prussian blue after an inhalation incident found that the benefit of treatment falls as initiation is delayed — most sharply for rapidly absorbed compounds — and concluded that therapy should begin as soon as possible after incorporation rather than waiting for complete dosimetry, and should be continued for weeks to months 6. This is why emergency plans authorize starting treatment on clinical suspicion of a significant intake.

Radionuclide(s) Countermeasure Mechanism FDA-approved indication Representative adult regimen
Plutonium, americium, curium Ca-DTPA then Zn-DTPA Chelation (renal excretion) Yes (2004) Ca-DTPA 1.0 g IV initial; Zn-DTPA for maintenance
Cesium-137, thallium Insoluble Prussian blue (Radiogardase) Ion exchange in gut; interrupts recirculation Yes (2003) 3 g orally three times daily, ≥ 30 days
Radioiodine (I-131, I-123) Potassium iodide (KI) Thyroid blocking Yes (thyroid blocking) Stable iodine before/at exposure (blocking, not decorporation)
Strontium, radium Oral phosphates, calcium/strontium loading Dilution / displacement / reduced uptake Not approved as decorporation drugs Supportive; per medical guidance
Uranium Supportive care; bicarbonate considerations Reduce nephrotoxicity, support excretion Not approved as decorporation drug Per medical guidance

Several entries (strontium, uranium, and KI as a blocker) are not FDA-approved decorporation drugs; they are supportive or preventive measures and must be directed by medical and health-physics judgment under the governing guidance 1, 5.

Clinical Impact

For a medical facility, the realistic internal-contamination scenarios are a radiopharmacy or therapy spill, a contaminated wound during dose preparation, or an inhalation during a spill cleanup. The contaminating radionuclide is usually a medical one — I-131, Tc-99m, F-18, Lu-177, or Ga-68 — rather than an actinide, so the on-hand countermeasures differ from a weapons-contamination scenario. Potassium iodide for radioiodine workers, aggressive wound irrigation, and prompt bioassay are the practical front line 1, 5.

The decisive factor in every case is speed of recognition and response. A worker who reports a needlestick or a spill promptly, is surveyed, and has bioassay initiated can be assessed and, if warranted, treated while countermeasures still work. A delayed report forfeits the window. This is why internal-contamination response is as much a training-and-culture problem as a pharmacology problem. For the broader emergency framework, see radioactive material spill response and contaminated patient emergency response.

Practical Optimization Tips

  • Pre-decide the pathway. The radiation protection program and emergency plan should name the plausible radionuclides, the countermeasures, the intake thresholds for action, and the physician who can order treatment — before an event.
  • Know what you stock and what you don't. Most imaging facilities will not stock DTPA or Prussian blue; identify the regional source (for example, a radiation emergency assistance center or poison-control pathway) and the KI you do keep for radioiodine work.
  • Start bioassay immediately. Collect baseline urine and nasal swabs at once; the first samples anchor the entire intake estimate and the decision to treat.
  • Treat on suspicion when the intake is clearly significant. For a large, credible intake, prompt treatment should not wait for a complete dose calculation — the averted dose is greatest early 6.
  • Document intake, assessment, and averted dose. The committed dose, the basis for treatment, and the averted dose belong in the exposure record and the incident report.
  • Rehearse it. A tabletop or drill for a wound or inhalation during dose handling exposes gaps in reporting, surveying, bioassay, and the medical pathway.

Regulatory Considerations

Internal dose is part of the occupational dose of record, so internal-contamination management is a regulated radiation-protection activity, not only a medical one. Under 10 CFR Part 20 (and Agreement State equivalents), the licensee must control and monitor intakes, sum internal and external dose into the total effective dose equivalent, and keep records; significant intakes and overexposures are reportable 9. The key references are:

  • NCRP Report No. 161 — the definitive handbook on managing persons contaminated with radionuclides, covering assessment, decision levels, and decorporation 1.
  • FDA labeling for Ca-DTPA and Zn-DTPA — the approved indications and dosing for actinide chelation 2, 3.
  • FDA labeling for Radiogardase (insoluble Prussian blue) — the approved indication and dosing for cesium and thallium 4.
  • 10 CFR Part 20 — occupational dose limits, monitoring of intakes, the TEDE concept, and recordkeeping and reporting 9.
  • IAEA Safety Reports Series No. 101 — medical management of radiation injuries, including internal contamination 8.

Facilities should fold internal-contamination response into the radiation protection program, the emergency plan, and worker training, and should keep the decision pathway and the drug-sourcing plan current. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey administer their own programs as NRC Agreement States, while Washington DC and Delaware are regulated directly by the NRC; verify which authority's reporting and dose-recording rules apply 9. DRPS supports this through radiation safety officer services, radiation safety training, and emergency-plan review.

Frequently Asked Questions (FAQs)

What is radionuclide decorporation?

Decorporation is the use of medical countermeasures to speed the removal of radioactive material that has been taken into the body, reducing the committed radiation dose. It includes chelating agents that bind metals for excretion, ion-exchange binders that trap radionuclides in the gut, and blocking or dilution agents that reduce uptake and retention. It is distinct from external decontamination, which only removes material from the skin and surfaces.

Which decorporation agent is used for plutonium and americium?

Calcium- and zinc-DTPA (pentetate calcium trisodium and pentetate zinc trisodium) are the FDA-approved chelating agents for internal contamination with plutonium, americium, or curium. Ca-DTPA is preferred in the first 24 hours after contamination, and Zn-DTPA is used for maintenance therapy afterward.

Which agent is used for cesium or thallium contamination?

Insoluble Prussian blue, marketed as Radiogardase, is the FDA-approved treatment for internal contamination with cesium-137 or thallium. It works by ion exchange in the gut, binding the radionuclide and interrupting its enterohepatic recirculation so more is excreted in stool rather than reabsorbed.

Why does the timing of decorporation matter so much?

Once a radionuclide is absorbed and distributed to tissues, it becomes harder to remove, and committed dose accrues continuously until the material is cleared or decays. Chelation and binding are most effective when the radionuclide is still in the bloodstream or gut, so treatment should begin as soon as possible after a confirmed or strongly suspected significant intake, often before full dose estimates are available.

Is potassium iodide a decorporation agent?

Not exactly. Potassium iodide is a thyroid-blocking agent: it saturates the thyroid with stable iodine so that radioactive iodine is not taken up and is instead excreted. It prevents uptake rather than removing material already incorporated, so it is a blocking countermeasure rather than a chelator, and it only protects the thyroid against radioiodine.

Who decides whether to start decorporation therapy?

The decision is a medical one, made by a physician, informed by the radiation safety officer or health physicist's intake and dose assessment. In an occupational setting, the facility's radiation protection program and emergency plan should pre-identify the agents, thresholds, and medical pathway so that treatment is not delayed during an actual event.

Key Takeaways

  • Internal contamination removes time, distance, and shielding as options — the dose comes from within until the material decays or is excreted, and decorporation is how excretion is accelerated.
  • DTPA chelates the actinides (Ca-DTPA first 24 hours, Zn-DTPA for maintenance); Prussian blue binds cesium and thallium in the gut.
  • Potassium iodide blocks rather than decorporates — it prevents thyroid uptake of radioiodine and does not remove incorporated material.
  • Timing dominates effectiveness: averted dose is greatest when treatment starts early, so credible significant intakes are treated on suspicion.
  • It is a regulated activity: internal dose counts toward TEDE under 10 CFR Part 20, and the response belongs in the radiation protection program, emergency plan, and training.

Conclusion

Decorporation is the part of radiation safety that applies when prevention has already failed and the hazard is inside the body. The physics is unforgiving — committed dose accrues continuously — but the chemistry offers real leverage if it is applied in time. A chelator that captures an actinide, or a binder that interrupts cesium recirculation, can avert a meaningful fraction of a serious committed dose, provided the intake is recognized and treated promptly.

For a medical facility, the goal is not to stock a pharmacy of antidotes but to build a response that works: fast recognition and reporting, immediate bioassay, a pre-decided medical and drug-sourcing pathway, and documentation that stands up to review. Most of the value is captured in the first hours, which means the program, not the pharmacology, is what determines the outcome.

How DRPS Can Help

Diagnostic Radiation Physics Services helps imaging and nuclear medicine facilities build defensible internal-contamination response into their radiation protection programs: intake and committed-dose assessment methods, bioassay program design, emergency-plan and spill-response review, worker training, and documentation aligned with NRC or Agreement State requirements and NCRP guidance.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware, through radiation safety officer services, radiation safety training, and medical physics consulting.

Related Resources

References

  1. National Council on Radiation Protection and Measurements. NCRP Report No. 161: Management of Persons Contaminated with Radionuclides: Handbook. Bethesda, MD: NCRP; 2008. ncrponline.org
  2. U.S. Food and Drug Administration. Pentetate Calcium Trisodium Injection (Ca-DTPA) prescribing information. Initial U.S. approval 2004. accessdata.fda.gov
  3. U.S. Food and Drug Administration. Pentetate Zinc Trisodium Injection (Zn-DTPA) prescribing information. Initial U.S. approval 2004. accessdata.fda.gov
  4. U.S. Food and Drug Administration. Radiogardase (Prussian blue insoluble) capsules prescribing information. Approved October 2, 2003. accessdata.fda.gov
  5. Dainiak N, Albanese J. Assessment and clinical management of internal contamination. J Radiol Prot. 2022;42(4):041001. doi:10.1088/1361-6498/aca0a7. PubMed
  6. Rump A, Stricklin D, Lamkowski A, Eder S, Abend M, Port M. The impact of time on decorporation efficacy after a "dirty bomb" attack studied by simulation. Drug Res (Stuttg). 2016;66(11):607-613. doi:10.1055/s-0042-112809. PubMed
  7. International Commission on Radiological Protection. ICRP Publication 119: Compendium of Dose Coefficients based on ICRP Publication 60. Ann ICRP. 2012;41(Suppl). icrp.org
  8. International Atomic Energy Agency. Medical Management of Radiation Injuries. Safety Reports Series No. 101. Vienna: IAEA; 2020. iaea.org
  9. U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. ecfr.gov